Tuesday, October 12, 2010

Daily Pump Trap: 10/12/10 edition

Good morning! Between October 8 and October 11, there were 36 new positions posted on the ACS Career website. Of these, 30 (83%) are academically connected.

Johnny-come-lately?: The Toyota Research Institute is hiring a Ph.D. chemist with experience in inorganic synthesis of materials for batteries. It's a temporary position (through Prymus) that's only offering 60-70k. Look, I'm just gonna say this once: this is a hot field. Dunno why Toyota is paying so low for a position that's been searched for by darn near everyone. Whoever gets this position will have two or three other offers in hand, I'll bet.

Huh: Sanofi-Aventis is looking for B.S./M.S. research associates in oncology chemistry (8+/5+ years experience desired, respectively.) Glad to see someone's hiring experienced folks.

Regulatory professional wanted: Dow-Corning desires a B.S. chemist with at least 3 years experience in regulatory affairs. It's at their Midland, MI facility; go Chemics. :-)

A broader look: For the search term "chemist", Indeed.com, Careerbuilder and Monster have (respectively) 4541, 295 and 667 postings.

2 comments:

  1. What the HELL is S-A doing?

    Sanofi cuts 1,700 U.S. jobs

    October 8, 2010 — 1:31pm ET | By Maureen Martino

    Sanofi-Aventis announced that it's restructuring its U.S. pharmaceutical operations. Of the French drugmaker's 13,000 U.S. employees, 6,900 work in the Pharmaceutical Operations division; Sanofi plans to cut 25 percent of the headcount there. The company will focus its work on diabetes, atrial fibrillation and oncology. The job cuts are part of a $2.8 billion cost-reduction plan announced last year, Sanofi spokesperson Jack Cox tells Bloomberg. Sales reps will be taking the brunt of the cuts, with 1,400 jobs being eliminated. A further 300 positions will be cut from the company's Bridgewater, New Jersey site.

    "Given the serious challenges facing our organization and the healthcare industry, it is important to act decisively now so that our organization has greater stability moving forward and that our resources are allocated to our strategic growth priorities," said Gregory Irace, CEO of Sanofi-Aventis U.S./Canada Pharmaceutical Operations. "These changes will foster a renewed focus on the strong growth and pipeline opportunities that will drive our vision of being a diversified healthcare leader."

    ReplyDelete
  2. Don't worry, they cut Ph.D positions to make room for these experienced BS/MS RAs. That way they can do the same amount of work but get cheated out of the big salary because they don't have the right letters after their name.

    ReplyDelete